Vector-mediated gene transfer offers a direct method of correcting genetic pulmonary diseases and might also be used to correct temporary abnormalities associated with acquired, nongenetic disorders. Because the fetus or newborn may be a more immune tolerant host for gene transfer using viral vectors, we used replication defective recombinant adenoviral vectors to test the feasibility of gene transfer to the fetal pulmonary epithelium in vitro and in vivo. Both proximal and distal epithelial cells in cultured fetal lung tissues from rodents and humans diffusely expressed the lacZ transgene 3 d after viral infection. In vivo gene delivery experiments were performed in fetal mice and lambs. Delivery of Ad2/CMV-I8Gal to the amniotic fluid in mice produced intense transgene expression in the fetal epidermis and amniotic membranes, some gastrointestinal expression, but no significant airway epithelial expression. When we introduced the adenoviral vector directly into the trachea of fetal lambs, the lacZ gene was expressed in the tracheal, bronchial, and distal pulmonary epithelial cells 3 d after viral infection. Unexpectedly, reactive hyperplasia and squamous metaplasia were noted in epithelia expressing lacZ in the trachea, but not in the distal lung of fetal lambs. 1 wk after infection, adenovirus-treated fetuses developed inflammatory cell infiltrates in the lung tissue with CD4, CD8, IgM, and granulocyte/macrophage positive immune effector cells. Transgene expression faded coincident with inflammation and serologic evidence of antiadenoviral antibody production. While these studies document the feasibility of viral-mediated gene transfer in the prenatal lung, they indicate that immunologic responses to El-deleted recombinant adenoviruses limit the duration of transgene expression. (J. Clin. Invest. 1995. 95:2620-2632
Introduction
Several recent studies support the feasibility of viral vectormediated gene transfer to epithelial tissues as an approach to the hepatocytes as an approach to correct CF liver disease and hemophilia (5, 6) . The recombinant adenovirus Ad2/CFTR-1 was successfully used to transfer CFTR cDNA to the human nasal epithelium in vivo (7) . Most gene transfer studies have focused on adult animals or humans and current trials of gene transfer for CF are being performed in adults. Recently, it has been reported that immunologic responses limit the duration of adenoviral-mediated gene expression (8, 9) . Stimulation of both the humoral and cellular immune systems has been noted with these vectors (8, 10) . Studies of gene transfer to the liver using MHC class I-deficient mice suggest that cytotoxic T lymphocyte responses to recombinant viral protein expression may limit the clinical utility of current El-deleted adenoviral vectors (11) .
One exception to the immunologic responses noted above is a report of long-term transgene expression in skeletal and cardiac muscle after adenoviral-mediated gene transfer in neonatal mice (12) . These findings suggest that the fetus or newborn may be a more immune tolerant host for gene transfer using recombinant adenoviruses. In ported (1, 13) . In Ad2/CMV-,6Gal, the viral early region 1 coding sequences Ela and Elb are replaced with the Escherichia coli lacZ gene driven by the CMV promoter. The vector retains the E3 region. Transgene expression is localized to the nucleus because a nuclear localization signal has been fused to /3-galactosidase. The phosphoglycerate kinase (PGK) promoter is used in Ad2/CFTR-2. The viral constructs are replication defective and are grown in the human embryonal kidney 293 cell line that complements the viral El gene products. Cells are freeze/thawed three times to release the virus, and the preparation is then purified on a CsCl gradient and dialyzed against PBS and 1% sucrose to remove CsCl as described previously (1) . Viral assays. Viral cultures were performed on the permissive 293 cells or on HeLa cells as described previously (1) . Serial Microscopy. Histochemistry was used to identify cells expressing the E. coli lacZ gene as described previously (1) . The left mainstem bronchus was ligated and the left lung was excised and frozen at -700C for use in immunohistochemistry studies or for PCR. The trachea and remaining lung tissue were fixed by instillation with 2% paraformaldehyde and 0.02% gluteraldehyde in PBS for 1 h, rinsed twice with PBS, and then incubated overnight in the X-gal reagent (5-bromo-4-chloro-3-indolyl-,i-D-galactopyranoside) at room temperature. 8-jpm-thick frozen sections were prepared from tissues embedded in OCT compound (Tissue-Tek; Miles Inc., Kankakee, IL). Alternatively, some fixed tissues were embedded in glycomethacrylate using standard techniques, and 2-4-pum-thick sections were prepared. LacZ-positive cells stain blue; the predominant staining is nuclear as the nuclear localization signal directs lacZ expression to the nucleus. Sections were examined to assess the surface epithelium cell types susceptible to adenoviral gene transfer (ciliated, nonciliated, basal) and for evidence of gene transfer to submucosal glands. Some specimens were fixed and embedded for transmission electron microscopy using standard techniques to document the nuclear localization of the gene product. We also looked for evidence of inflammation after viral infection by examining hematoxylin and eosinstained sections for the presence of inflammatory cell infiltrates and by performing immunohistochemistry. For each experimental or littermate control animal, two to four tissue blocks from areas of the trachea (proximal, middle, and distal) and each lobe of the right lung (apical, middle, diaphragmatic, and accessory) were examined histochemically. Hematoxylin and eosin sections were scored for inflammation semiquantitatively from 0 to 4+. Sections were also examined by two pathologists unaware of the treatment the animals received.
To quantify transgene expression, we studied X-gal-stained, plasticembedded sections from the trachea and lung tissue of the eight animals that received Ad2/CMV-f3Gal. Differential cell counts were performed at three levels of the trachea (proximal, middle, and distal) and two lobes of the right lung (apical and diaphragmatic). Sections were selected randomly from the same site in each animal and examined under oil immersion at a magnification of Reverse transcriptase (RT)-PCR. We used RT-PCR to detect vector-generated mRNA in lung tissues from fetal lambs as described previously (10) . Primers were similar to those reported previously with the exception of the substitution of promoter-specific sequences as follows: PGK 5' CGG AGC GCA CGT CGG CAG TCG G 3', PGK 5' GCT CCC TCG TTG ACC GAA TCA CCG ACC 3' (10, 13). Lung samples were snap frozen in liquid nitrogen and stored at -70°C until used. Total RNA was isolated using the single-step chloroform/phenol extraction method, and 2 ,1 of RNA was reverse transcribed using the GeneAmp RNA PCR kit (Perkin-Elmer Corp., Norwalk, CT) ( 17). For a negative control, reverse transcriptase was omitted from the reaction mixture. A 10-iu1 aliquot of the PCR product was electrophoresed on a 1% agarose gel and visualized with ethidium bromide.
In vitro models. 12-13-d gestation fetal rat lung explants were grown in culture using methods similar to those described previously (18) . Timed pregnant (sperm positive = day 0) Sprague-Dawley rats were killed with CO2 inhalation, and the fetuses were removed by hysterotomy and placed in sterile Hanks' balanced salt solution at 4°C. Fetal lungs were removed and placed in 35-mm tissue culture dishes precoated with 0.8 ml of Waymouth's media with 1% FCS and 100 U/ml penicillin/100 /ig/ml streptomycin. After overnight incubation at 37°C/5% CO2 in air, during which the tissues adhered to the dishes, the samples were placed on a rocking platform at 3 oscillations/min. The media were changed daily. Similar experiments were performed with cultured explants of midgestation human fetal lung as previously described ( 19) .
The adenoviral vector (Ad2/CMV-,/Gal, 2 x 10'0 IU/ml) was introduced into the lumen of fetal lung tissue explants via a micropipette and a pressure-driven apparatus (Picospritzer; General Valve Corp., Fairfield, NJ). From 0.5 to 4 p1 of virus ( I07-8 x I07 IU) was injected into each explant (n = 32 rat and 48 human explants). The exact volume delivered is approximate, as some viral suspension always leaked from the injection sites. 3 d after the injection, tissues were fixed and stained with X-gal.
In vivo models. We used techniques of in utero manipulation of the mouse embryo to introduce either a labeling dye or recombinant adenovirus into the amniotic fluid (20, 21) . To test the feasibility of this method of gene delivery to the lung, 5-50 IL of 2% fast green dye (Sigma Immunochemicals, St. Louis, MO) or the fluorescent dye 1,1-dioctadecyl-3,3,3 ',3 '-tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes, Inc., Eugene, OR) was introduced into the amniotic cavity (22) . DiI was prepared as a 0.5% solution in 100% ethanol, diluted 1:100 in 0.3 M sucrose and warmed to 370C before injection.
24-72 h later, the animals were killed, and fetal tissues were examined for rhodamine fluorescence. Similar methods were then used to introduce Ad2/CMV-f3Gal into the amniotic cavity.
Fetal lamb surgical procedures were performed under sterile conditions using previously described techniques (23) . 18 lambs of 90-110 d of gestation were used in these experiments (term = 145 d); each experiment used twin gestations with gestational ages determined based on the induced ovulation technique (23) . Two methods were used to introduce the viral suspension into the lung. Briefly, the ewe was fasted 24 h before surgery and anesthetized using mixtures of halothane ( 1% ), oxygen (33%), and nitrous oxide (66%). Under sterile conditions, the uterus was opened over the fetal head, and the head and neck of the fetus were exteriorized. In 17 animals a tracheotomy was performed, and a 5 French balloon-tipped catheter was inserted into the trachea and inflated. Ad2/CMV-,lBGal (six animals 1 x 1010 HU, two animals 3 x 10 0 IU), Ad2/CFTR-2 (three animals 1 X 1010 IU, two animals 3 x 10'°IU), or normal saline (five animals) was mixed in 2 or 20 ml of normal saline and injected into the lower trachea of 17 fetuses through the catheter. This dose was extrapolated from a previous safety and efficacy study in cotton rats and was expected to transduce a significant number of epithelial cells (10) . The balloon catheter was deflated 3 h after the virus was instilled. In one animal, the head and neck were exteriorized, the thyroid cartilage was identified, and 1 x 1010 IU of Ad2/CMV-3Gal was injected into the tracheal lumen through a needle.
The fetuses were then returned to the uterus. Animals were killed at intervals of 3 (8 animals), 4 (2 animals), 7 
Results
In vitro gene transfer to fetal lungs Organ cultures have been used as model systems to study the developing lung because many aspects of their morphology and function parallel in vivo development. Therefore we tested the ability of an adenoviral vector to transfer a gene to fetal rat and human lung in organ culture. 3 d after injection of Ad2/CMV3Gal, X-gal-stained fetal rat lung tissues showed evidence of both diffuse and patchy epithelial cell lacZ gene expression ( Fig. 1 , A, C, and D). In some sections virtually all epithelia stained blue, whereas in other areas lacZ expression was patchy. Sites far removed from the point of injection expressed little or no transgene. These findings probably reflect the unequal distribution of injected virus within the fluid-filled airway lumen. Occasionally we saw blue-stained cells in the mesenchyme. LacZ expression in nonepithelial cells probably represents areas exposed to the virus when the micropipette was inserted, as it was not always possible to selectively inject virus into the lumen alone. LacZ-expressing epithelial cells included those in the conducting airways and the distal lung. Noninjected tissues showed no evidence of endogenous /3-galactosidase activity or blue stained nuclei (Fig. 1 B) . To (24) . These in vitro studies indicate that the adenoviral vector can transfer a cDNA to murine and human fetal pulmonary epithelia and direct expression of recombinant protein.
In vivo gene transfer to fetal lungs Fetal mice. The most simple approach to deliver a vector to fetal pulmonary airways would be to introduce the vector into the amniotic fluid. We hypothesized that fetal breathing activity might allow the vector access to the fetal lung (25) . To test this possibility, we first developed the in utero techniques of amniotic cavity injection by introducing 2% fast green dye into the amnions of fetal mice using a micropipette attached to a syringe. With this approach we successfully stained the amniotic cavity in 60% of the fetuses (data not shown). Therefore the amniotic cavities of 15-d gestation fetal mice were injected with 5-50 M1 of Dii. Examination of the fetuses 24-72 h later revealed diffuse epithelial cell staining of the pulmonary (Fig.  2 , A-D) and gastrointestinal tracts. Fluorescent staining was also present in the epidermis but not in other fetal organs. The pulmonary epithelial cell staining extended from the trachea to the distal acinar tubules (Fig. 2, A-D ). These observations indicate that the marker dye in amniotic fluid reached the pulmonary epithelium, possibly during episodes of fetal breathing with the glottis open.
The preliminary experiments with dyes suggested that a vector introduced into amniotic fluid might reach pulmonary epithelial cells. In subsequent experiments 5-50 kll of viral suspension was injected into the amniotic cavities of 15-d gestation mouse embryos. 2 d later the fetuses were removed and fixed and stained with X-gal. While this approach achieved abundant lacZ gene expression in the skin, oropharynx, and, to a lesser extent, the gastrointestinal tract of the fetus, we saw no significant staining of the pulmonary epithelium (n = 10, Fig.  2 , E and F). Control, untreated animals showed no blue-stained cells. The lack of pulmonary cell labeling in virus-treated fetuses suggests that diffuse infection of the fetal epidermal and amniotic membrane surfaces may have significantly reduced the amniotic fluid viral titer and thus decreased the amount of virus that could be transferred to the lung. Alternatively, the diffusion and flow of the virus may have been more restricted than the smaller dyes. Therefore we examined the effect of direct instillation of virus into the fetal airway.
Fetal lambs. The fetal lamb was used for these in vivo studies because its large size allowed easy manipulation and direct introduction of the vector into the fetal lung through ex utero approaches. Furthermore, submucosal from < 1% to 28% with the 2-ml instillation volume. In contrast, when the instillation volume was increased to 20 ml, more distal lung cell expression was evident (Fig. 4 , E and F; Table  I ). The percentage of f3Gal-positive cells was greater in the lungs in which the virus was instilled through a catheter with the balloon inflated than when the virus was introduced by transtracheal injection (Table I) . Microscopically, blue staining was nuclear and localized to epithelial cells. To verify that the histochemical pattern was consistent with transgene expression we also performed electron microscopy. The nuclear localization of the lacZ gene product was confirmed using transmission electron microscopy (not shown (Fig. 4) . Therefore, the virus directed transfer of the reporter gene to all cell types of the tracheal epithelium. We did not observe blue-stained nuclei in subepithelial cells. In regions of the trachea where the transgene was expressed, epithelial cells were noted to exhibit variable morphology (Fig.  4) . In areas where lacZ-expressing cells were infrequent or absent, the normal columnar epithelium with pseudopalisading was preserved. However, in the areas where a greater number of cells expressed the transgene, reactive changes were noted in the epithelium. These changes included areas of reactive hyperplasia and squamous metaplasia with loss of the normal morphology (Fig. 4, B-D) . In these areas the columnar epithelium was replaced with stratified squamous epithelial cells and there was a loss of cilia (Fig. 4 D) . The morphologic changes were only noted in the areas where lacZ expression was observed. These changes were found in the trachea of the animal in which the virus was introduced through a needle and in the trachea of catheterized animals below the level of the catheter tip. Therefore these alterations do not appear to be due to mechanical injury of the trachea. This pattern was not observed in areas that did not show blue-stained cells or in littermate control animals that received saline.
We also were interested in whether fetal submucosal gland cells were accessible to gene transfer using this technique. Localization studies of CFTR mRNA and protein expression have shown that levels of expression in submucosal glands are greater than in the surface epithelium, suggesting that gene transfer to both the surface epithelium and submucosal glands may be important therapeutically (27) . Occasional blue cells were seen in the apical lining cells of the submucosal glands but not in the deeper portions of the gland structure. Transgene expression was also seen in the nonciliated cuboidal epithelial cells of the distal pulmonary epithelium of the pseudoglandular stage lung, especially in the animals that received the 20-ml volume of instillate (Fig. 4 , E and F; Table I ). When the virus was instilled with 20-ml volumes, the percentage of fiGal-positive distal pulmonary epithelial cells ranged from 1 to 12% (Table I) . Because cDNA to the fetus. We used RT-PCR to determine if the cDNA was transcribed after administration of Ad2/CFT1R-2. As shown in Fig. 5 , the Ad2/CFTR-2-treated fetus expressed CFTR mRNA in the lung 3 d after tracheal instillation. A concern with viral-mediated gene delivery approaches is the potential for the host to develop an immune response to the vector. Hematoxylin and eosin sections were prepared, and we looked for evidence of cellular immune responses in tissues from all experimental time points (Fig. 6) 603 bp -* macroscopically or microscopically in glycomethacrylate-embedded sections. Less than 1% of the pulmonary epithelial cells stained blue with X-gal on the more sensitive frozen sections of the tissues, a frequency strikingly less than at days 3 or 4 (Table I) . Similarly, in one experiment of 2-wk duration, no blue-stained cells were visible macro-or microscopically except in frozen sections (Fig. 5) . Inflammatory cells were present in a distribution similar to the 1-wk experiment, although the density of the infiltrates was less (data not shown). Tracheal specimens were examined from the 7-, 8-, and 14-d time points to assess the evolution of the reactive changes noted at 3 d. While no blue cells were present, areas of reactive hyperplasia were noted at a lower frequency than at days 3 and 4, suggesting that this process was resolving (data not shown).
To characterize the immune effector cells present in the lung, we performed immunohistochemistry using specific monoclonal antibodies against granulocyte/macrophage, CD4, CD8, and IgM markers (Fig. 6) . At 3 and 4 d after infection, granulocyte/macrophage, CD4, CD8, and IgM marker-positive cells were seen more frequently in the experimental animals than littermate controls. At 7 and 8 d after infection, a marked immune response was seen consisting primarily of CD4, CD8-positive cells in addition to IgM and granulocyte/macrophagemarker positive cells. At the same time viral-treated animals, but not the littermate controls, developed serologic evidence of antiadenoviral antibody production by ELISA assay (data not shown). The antibodies detected are of fetal origin as the ovine placenta is impermeable to maternal antibodies (28) . A similar inflammatory response was present in the 2 wk experiment, although the number of inflammatory cells was less compared with 1 wk (data not shown). Similar immune effector cells were present in the Ad2/CMV-3Gal-and Ad2/CFTR-2-treated fetuses.
To determine the stability of the virus in vivo we assayed serial amniotic fluid samples. (2, 10) . The rationale for the present studies was the notion that a fetus might be an immune tolerant host for adenoviral-mediated gene transfer to the lung. Studies of the ontogeny of immunity in human and other mammalian fetuses document that the fetal immune system has both qualitative and quantitative differences in the ability to mount T and B lymphocyte-mediated responses to a variety of infectious agents (28, 31, 32) . In the human fetus, B lymphocytes are first detected beginning at 9 wk of gestation, and similarly T lymphocytes are present by [10] [11] [12] wk of gestation (31 ) . With appropriate stimulation human fetal cells may produce antibodies or show functional T cell responses, while in other circumstances they exhibit tolerance to antigenic challenges. Similarly, while fetal sheep may exhibit immunologic tolerance under some circumstances, humoral and cell-mediated immune responses are also well documented in vivo (32) .
While pulmonary epithelial cell gene transfer with recombinant adenoviruses is effective in some short-term studies (2, 10, 33) , recent reports suggest that dose-dependent immune responses limit the duration of gene expression using these vectors (8, 11, 34) . Yang and colleagues (34) found that low-level viral gene expression occurs with liver-directed gene transfer using an El-deleted adenovirus. Their findings suggest that a virus-specific cellular immune response may lead to the destruction of the genetically modified hepatocytes (34) . Further studies using mice deficient in CD8 + lymphocytes are consistent with the hypothesis that MHC class I-restricted CD8+ cytolytic T cells are the primary immune effectors causing loss of transgene expression in this model ( 11) . Gene transfer with recombinant adenoviruses has also been associated with stimulation of the humoral immune system and production of neutralizing antibodies (10) .
Unexpectedly, gene transfer to the large airways in the fetal lamb was associated with morphologic changes of reactive hyperplasia and squamous metaplasia in areas of transgene expression 3 and 4 d after gene transfer. To our knowledge the morphological changes in many tracheal epithelial cells incorporating the transgene 3 d after infection have not been observed before. These nonspecific changes of cellular hyperplasia and squamous metaplasia appeared reactive, presumably reflecting a cellular response to the viral infection. Similar morphologic changes were seen in aimals that received the CFIR vector Ad2/CFTR-2, indicating that this response is unlikely to be due to the expression of /3-galactosidase. Temporally these changes preceded the inflammatory cell infiltrates that were seen 1 wk after gene transfer. These morphologic changes were not observed in cultured rat or human explants, suggesting either that the findings are species specific or that they are due to factors only present in vivo.
There are several possible explanations for this finding. The first is that viral antigens or viral gene expression and protein production stimulate cell growth and differentiation. Low levels of some adenoviral early and late gene products (E4 and L5) may be expressed by the recombinant virus, and these gene products could modulate cell growth (1). Bronchial xenografts infected with an El-and E3-deleted adenovirus showed low levels of viral fiber protein production and E2a gene product (30) . We also observed low levels of E2a expression by Northern blotting in the lungs of adenoviral-treated fetuses (our unpublished observation). It is also possible that host factors could substitute for deleted viral products and allow viral protein pro- duction. This has been demonstrated in the case of Ela-deleted adenoviruses in HepG2 cells where NF-IL6 acts as a sequencespecific cellular nuclear factor regulating Ela-responsive genes in the absence of Ela (35, 36 (30) .
A potential advantage of fetal gene transfer is the possibility of permanently correcting a genetic defect early in life, before irreversible organ damage occurs. Since the total number of epithelial cells in the fetal lung is significantly less, it is possible that fewer cells would need to be corrected by gene transfer in the fetus. While adenovirus can transfer genes to cells regardless of their proliferative state, the frequency of adenoviral integration into chromosomal DNA is very low, and gene expression is expected to be episomal and transient. Gene transfer to the pulmonary epithelium of the fetus might be particularly advantageous using a vector that integrates into the host genome (retrovirus or adeno-associated virus). This might allow passage of the transgene from progenitor to daughter cells, thereby increasing the population of corrected cells in the lung.
There are several conditions where gene transfer to the somatic cells of the fetal or neonatal lung might have applications. First, transfer of surfactant protein genes or antioxidant genes to the lung of the preterm infant could enhance surfactant production and protect the pulmonary epithelium from oxygeninduced lung injury associated with the treatment of neonatal respiratory distress syndrome (39 (40, 41) . Third, the perinatal transition to air breathing is facilitated by active absorption of sodium through amiloride-sensitive epithelial sodium channels (42) . Maladaptions of this process may contribute to lung disease in premature and term infants (43) ; such problems might be addressed by introducing the epithelial sodium channel genes into the lung of the infant (44, 45) . Fourth, it may be advantageous to begin CF gene therapy early in life, prenatally or neonatally, to prevent the onset and progression of chronic lung disease. There is now evidence that infants with CF have pulmonary inflammation and altered lung function in infancy before they develop clinical symptoms of respiratory disease or are colonized with bacteria (46, 47) .
Finally, vector-mediated gene transfer may be a useful technique to study lung cell lineage and the developmental regulation of genes introduced into the fetal lung.
In summary, while a replication-defective adenoviral vector 2630 was effective for short-term gene transfer to fetal pulmonary epithelia in vitro, gene transfer in vivo in fetal lambs was shortlived and associated with significant cellular and humoral immune responses. These results suggest that current El-deleted adenoviral vectors are ineffective for gene transfer in the fetus. Several strategies may be proposed to circumvent the fetal immune response to the vector and deserve further study. Additional deletions or alterations of the viral backbone to reduce viral protein expression may blunt the fetal immune response. It may also be possible to tolerize a fetus by administering lower doses of virus, perhaps at an earlier developmental time point. The fetal immune response could be minimized or prevented using pharmacologic immunosuppressive agents or specific monoclonal antibodies against immune effector cells. Successful gene transfer to the fetal or neonatal lung will require further modifications of the adenoviral vector system or alternative vector approaches.
